Disclosure: This is an affiliate site. We may earn compensation from partners. Full disclosure | Medical disclaimer
Three approved non-diabetes indications now exist — and which one you are prescribed under can decide whether your insurance pays.
GLP-1 medications entered public consciousness as weight-loss drugs, but the regulatory picture has moved well past that. Beyond type 2 diabetes, this class now holds approved indications for weight management, cardiovascular risk reduction and obstructive sleep apnea, with a separate kidney indication for semaglutide in diabetes.
That matters clinically, because these are meaningful outcomes rather than cosmetic ones. It also matters financially in a way that is easy to miss: many insurance plans exclude medications used solely for weight loss, but cover the same drug when it treats a different diagnosed condition.
This guide covers what is actually approved, what the trials showed, and what remains promising but unproven — a distinction that matters, because a lot of coverage blurs the two.
These are FDA-approved uses with specific labelled populations. Note how narrow each population is.
| Medication | Indication | Population | Key trial result |
|---|---|---|---|
| Wegovy (semaglutide 2.4 mg) | Reduce risk of major adverse cardiovascular events | Adults with obesity or overweight and established cardiovascular disease | SELECT: roughly 20% reduction in MACE — cardiovascular death, heart attack and stroke |
| Zepbound (tirzepatide) | Moderate-to-severe obstructive sleep apnea | Adults with obesity and moderate-to-severe OSA | SURMOUNT-OSA: 58.7% AHI reduction vs 2.5% on placebo |
| Ozempic (semaglutide 1.0 mg) | Reduce risk of kidney disease worsening, kidney failure and cardiovascular death | Adults with type 2 diabetes and chronic kidney disease | FLOW: 24% relative risk reduction in kidney disease progression, kidney failure and CV death |
Being outside the labelled population does not mean the drug will not help you — it means you do not qualify for that specific indication, which is what insurers assess.
If your plan excludes weight-management medication, an approved indication for a condition you actually have can change the answer. The American Academy of Sleep Medicine notes that some Medicare plans with drug coverage may cover Zepbound for treating obstructive sleep apnea but not for weight loss alone. Sleep apnea, cardiovascular disease and chronic kidney disease are all substantially underdiagnosed — it is worth asking your clinician whether you should be screened.
In March 2024, the FDA approved Wegovy to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease who are also obese or overweight. It was the first treatment approved specifically to reduce serious heart problems in this population.
The approval rested on the SELECT trial, which enrolled people with overweight or obesity and established cardiovascular disease but without diabetes. Semaglutide 2.4 mg significantly reduced major adverse cardiovascular events — a composite of cardiovascular death, non-fatal heart attack and non-fatal stroke — by roughly 20%.
This reframed the drug class. A 20% reduction in hard cardiovascular outcomes is the kind of result that changes prescribing guidelines, and it applies to both the Wegovy injection and the 25 mg tablets.
The population requirement is specific: you need established cardiovascular disease alongside obesity or overweight. Cardiovascular risk factors alone do not meet the labelled indication.
The FDA expanded Ozempic's approval to reduce the risk of kidney disease worsening, kidney failure and death from cardiovascular disease in adults with type 2 diabetes and chronic kidney disease — making semaglutide the only GLP-1 receptor agonist with that indication.
The evidence came from the FLOW trial, in which weekly semaglutide 1.0 mg produced a 24% relative risk reduction in a composite of kidney disease progression, kidney failure and cardiovascular death. The trial showed semaglutide slows the decline in eGFR, the standard measure of kidney function.
This one is narrower than the others: it requires both type 2 diabetes and chronic kidney disease. It does not extend to people with CKD who do not have diabetes.
For anyone with diabetic kidney disease, this is a genuinely significant development — kidney disease progression has historically had few interventions that alter its course.
Zepbound became the first and only prescription medication approved for obstructive sleep apnea, for moderate-to-severe OSA in adults with obesity. Before this, OSA had no drug treatment at all.
In the SURMOUNT-OSA trials, patients on Zepbound saw a 58.7% reduction in the apnea-hypopnea index against 2.5% on placebo, with Lilly reporting mean AHI reductions of up to 63% — around 30 fewer breathing events per hour — alongside 18% to 20% weight loss.
The mechanism is largely weight-mediated: less weight means less airway obstruction. That is not a criticism, but it does mean the benefit depends on sustaining the weight loss.
We cover this indication in more depth on its own page, including what it means for CPAP and how the coverage angle works.
Research has linked GLP-1 use to reduced risk of several substance-related disorders including alcohol-use disorders, and to potential benefits across liver disease, arthritis and inflammation. Review literature describes expanding benefits across cardiovascular, kidney, liver, arthritis and sleep outcomes. None of these are FDA-approved indications. Association in observational data is not the same as a demonstrated treatment effect, and no clinician can prescribe a GLP-1 for alcohol use disorder as an approved therapy today.
Beyond type 2 diabetes and weight management, there are three approved non-diabetes indications in this class: Wegovy to reduce major adverse cardiovascular events in adults with obesity or overweight and established cardiovascular disease; Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity; and Ozempic to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
Yes, that is an approved indication. The FDA approved Wegovy in March 2024 to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease who are obese or overweight, based on the SELECT trial which showed roughly a 20% reduction in major adverse cardiovascular events.
Yes, for a specific population. Ozempic is approved to reduce the risk of kidney disease worsening, kidney failure and death from cardiovascular disease in adults with type 2 diabetes and chronic kidney disease. The FLOW trial showed a 24% relative risk reduction in that composite outcome. It does not extend to people with CKD who do not have type 2 diabetes.
Often, yes. Many plans exclude medications used solely for weight loss but cover the same drug for a diagnosed condition with its own indication. The American Academy of Sleep Medicine notes some Medicare plans may cover Zepbound for obstructive sleep apnea but not weight loss alone. If you have been denied, ask your clinician whether you should be screened for OSA or assessed against the cardiovascular or kidney indications.
Research has found associations between GLP-1 use and reduced risk of several substance-related disorders, including alcohol-use disorders. This is not an FDA-approved indication, and observational association is not the same as demonstrated treatment effect. No clinician can prescribe a GLP-1 as an approved therapy for alcohol use disorder today.
Only Zepbound (tirzepatide), for moderate-to-severe obstructive sleep apnea in adults with obesity. It is the first and only prescription medication approved for OSA. Wegovy and Ozempic do not carry this indication.
Not as of this review. Review literature describes expanding benefits across cardiovascular, kidney, liver, arthritis and sleep outcomes, but only the cardiovascular, kidney and sleep apnea indications have been approved. The rest remains research rather than approved treatment.
The OSA indication in depth
Using an indication to get covered
$50/month for eligible beneficiaries
Who qualifies, and for what
Different drugs, different indications
What is coming next
Claims on this page trace to the following sources, checked on August 30, 2026.
Explore more expert guides and reviews to help you on your weight loss journey
Complete guide explaining the difference between semaglutide, Ozempic, Wegovy, and compounded semaglutide.
Complete guide to Jardiance weight loss: how much to expect, mechanism, and comparison to GLP-1 medications.
The SURMOUNT-5 head-to-head trial: 20.2% vs 13.7% average weight loss, plus side effects and cost.
What actually differs, what the FDA changed in 2026, and how the price gap closed.
The oral GLP-1 pill approved April 1, 2026: dosing from 0.8 mg, pricing from $149/mo, and results.
The higher-dose semaglutide approved March 19, 2026, delivering 20.7% mean weight loss.
This article summarizes FDA approval information and published clinical trial results and is for informational purposes only. It is not medical advice, a diagnosis, or a treatment recommendation. Approved indications have specific labelled populations, and only a qualified healthcare provider can determine whether any GLP-1 medication is appropriate for you. Emerging research described here as unapproved should not be used as a basis for treatment decisions. This page contains affiliate links, and we may earn compensation if you use them.
Date reviewed: August 30, 2026